Table 3.

Selected trials of neuraminidase inhibitors for treatment of influenza infections

Drug	Study population	Reduction in the median time to alleviation of symptoms (days)	Reference
Zanamivir	Healthy adults with laboratory-confirmed influenza	1	Monto et al. (1999b)
Zanamivir	Healthy adults with laboratory-confirmed influenza	1	Hayden et al. (1997)
Zanamivir	Healthy adults with laboratory-confirmed influenza	1.5	The MIST Study Group (1998)
Zanamivir	Healthy adults with laboratory-confirmed influenza	2.5	Makela et al. (2000)
Zanamivir	Children (5–12 years) with laboratory-confirmed influenza	1.25	Hedrick et al. (2000)
Zanamivir	Healthy adults with laboratory-confirmed influenza (meta-analysis)	1.25	Cooper et al. (2003)
Zanamivir	Children with laboratory-confirmed influenza (meta-analysis)	1	Cooper et al. (2003)
Zanamivir	High-risk patients with laboratory-confirmed influenza (meta-analysis)	2.0	Cooper et al. (2003)
Zanamivir	High-risk patients with laboratory-confirmed influenza (meta-analysis)	2.5	Lalezari et al. (2001)
Oseltamivir	Healthy adults with laboratory-confirmed influenza	1.3	Treanor et al. (2000)
Oseltamivir	Healthy adults with laboratory-confirmed influenza	1.2 (75 mg), 1.45 (150 mg)	Nicholson et al. (2000)
Oseltamivir	Children (1–12 years) with laboratory-confirmed influenza	1.5	Whitley et al. (2001)
Oseltamivir	Healthy adults with laboratory-confirmed influenza (meta-analysis)	1.4	Cooper et al. (2003)
Oseltamivir	Children with laboratory-confirmed influenza (meta-analysis)	1.5	Cooper et al. (2003)
Oseltamivir	High-risk patients with laboratory-confirmed influenza (meta-analysis)	0.4	Cooper et al. (2003)

Note: Treatment was initiated within 48 h of the onset of symptoms.